MétaCan
Menu
Back to cohort
Record W4400271292 · doi:10.1016/j.jinf.2024.106217

Short- and long-term effects of imatinib in hospitalized COVID-19 patients: A randomized trial

2024· review· en· W4400271292 on OpenAlexaff
Alex L E Halme, Sanna Laakkonen, Jarno Rutanen, Olli Nevalainen, Marjatta Sinisalo, Saana Horstia, Jussi M. J. Mustonen, Negar Pourjamal, Aija Vanhanen, Tuomas Rosberg, Andreas Renner, Markus Perola, Erja‐Leena Paukkeri, Riitta-Liisa Patovirta, Seppo Parkkila, Juuso Paajanen, Taina Nykänen, Jarkko Mäntylä, Marjukka Myllärniemi, Tiina Mattila, Maarit K. Leinonen, Alvar Külmäsu, Pauliina Kuutti, Ilari Kuitunen, Hanna‐Riikka Kreivi, Tuomas P. Kilpeläinen, Heikki Kauma, Ilkka Kalliala, Petrus Järvinen, Riina Hankkio, Taina Hammarén, Thijs Feuth, Hanna Ansakorpi, Riikka Ala-Karvia, Gordon Guyatt, Kari A.O. Tikkinen

Bibliographic record

VenueJournal of Infection · 2024
Typereview
Languageen
FieldMedicine
TopicLong-Term Effects of COVID-19
Canadian institutionsMcMaster University
FundersHengityssairauksien TutkimussäätiöFilhaTampereen TuberkuloosisäätiöTaysSuomen Lääketieteen SäätiöSigrid Juséliuksen SäätiöPäivikki ja Sakari Sohlbergin Säätiö
KeywordsCoronavirus disease 2019 (COVID-19)ImatinibMedicineTerm (time)2019-20 coronavirus outbreakRandomized controlled trialSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineIntensive care medicineVirologyOutbreakDiseaseInfectious disease (medical specialty)

Abstract

fetched live from OpenAlex

OBJECTIVES: We studied the short- and long-term effects of imatinib in hospitalized COVID-19 patients. METHODS: Participants were randomized to receive standard of care (SoC) or SoC with imatinib. Imatinib dosage was 400 mg daily until discharge (max 14 days). Primary outcomes were mortality at 30 days and 1 year. Secondary outcomes included recovery, quality of life and long COVID symptoms at 1 year. We also performed a systematic review and meta-analysis of randomized trials studying imatinib for 30-day mortality in hospitalized COVID-19 patients. RESULTS: We randomized 156 patients (73 in SoC and 83 in imatinib). Among patients on imatinib, 7.2% had died at 30 days and 13.3% at 1 year, and in SoC, 4.1% and 8.2% (adjusted HR 1.35, 95% CI 0.47-3.90). At 1 year, self-reported recovery occurred in 79.0% in imatinib and in 88.5% in SoC (RR 0.91, 0.78-1.06). We found no convincing difference in quality of life or symptoms. Fatigue (24%) and sleep issues (20%) frequently bothered patients at one year. In the meta-analysis, imatinib was associated with a mortality risk ratio of 0.73 (0.32-1.63; low certainty evidence). CONCLUSIONS: The evidence raises doubts regarding benefit of imatinib in reducing mortality, improving recovery and preventing long COVID symptoms in hospitalized COVID-19 patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.017
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.557
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.017
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0060.002
Bibliometrics0.0020.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.381
Teacher spread0.360 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designRandomized trial
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of InfectionSame topicLong-Term Effects of COVID-19French-language works237,207